Eurofins Opens New UK Analytical Testing Facility

News
Article

Eurofins Scientific has opened a £4-million (US$5-million) pharmaceutical chemistry and microbiology facility in Livingston, Scotland, to support the company’s product and water testing businesses in the UK.

On Sep. 29, 2017, Eurofins Scientific, a life sciences company specializing in analytical testing, opened a previously announced pharmaceutical chemistry and microbiology facility in Livingston, Scotland, following a £4-million (US$5-million) investment.

The 5800m2-facility, which will move to Livingston from its current site in Newbridge, Edinburgh, Scotland, will provide greater capacity for the company’s biopharmaceutical product testing business. The site will also facilitate new laboratories for the company’s water testing business, which provide analysis to assess the safety of water in cooling towers, hot and cold water systems, closed systems, and recreational waters such as swimming pools and spas.

The company’s product testing business will look to expand on finished product and raw materials testing. According to the company, employee numbers are anticipated to double to more than 100 in the next few years, with an increased number of technical specialists being added to work on method development and validation.

Additionally, the site will focus on GMP microbiology contract testing, with equipment being added to improve inductively coupled plasma mass spectrometry testing. The company will also invest in liquid chromatography equipment, which is expected to increase efficiency by 40%.

The investment follows the company’s acquisition of Exova’s pharmaceutical, food, and water testing business in the UK & Ireland in July 2016, and the subsequent purchase of ILS’s pharmaceutical business in October 2016.

In related news, the company announced an agreement to acquire EAG Laboratories, a scientific services company specializing in analytical and testing services to the agrochemical and pharmaceutical industries, from Odyssey Investment Partners, in September 2017. The transaction is expected to close within a few months following this announcement, subject to customary closing conditions.

Source: Eurofins

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content